Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy  – USA, 2018-05-15 19:04 (1251 d 07:31 ago) – Posting: # 18764
Views: 2,151

Dear bebac_fan,

» I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.
»

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Regards,

Scopy

Complete thread:

Activity
 Admin contact
21,731 posts in 4,544 threads, 1,543 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time: Monday 02:35 CEST (Europe/Vienna)

Law is mind without reason.    Aristotle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5